Breaking News

Prothena, Roche Initiate Development Pact

By Kristin Brooks | January 23, 2014

Triggers $30 million upfront payment from Roche

Prothena Corp., under its license, development, and commercialization agreement with Roche, will receive the $30 million upfront payment from Roche, triggered by the expiration of the Hart-Scott-Rodino waiting period. The companies entered the worldwide collaboration in December 2013 to develop and commercialize antibodies that target α-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease, which is currently in preclinical development and is expected to enter Phase I trials this year.
 
"This initial payment of $30 million marks the beginning of Prothena's collaboration with Roche, to co-develop and potentially co-commercialize PRX002," said Dale Schenk, Ph.D., president and chief executive officer of Prothena. "Prothena and Roche aim to develop PRX002 as a disease modifying treatment for Parkinson's disease and potentially other synucleinopathies, and so we very much look forward to working with Roche to initiate Phase I studies for PRX002 in the coming months.

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems